Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Disease burden of Hepatitis B-related hepatocellular carcinoma

This month's issue of the Journal of Viral Hepatitis examines Hepatitis B-related hepatocellular carcinoma.

News image

fiogf49gjkf04

Worldwide, 350 million people are chronically infected with hepatitis B virus  who are at greater risk of hepatocellular carcinoma compared with uninfected people.

Dr Nguyen and colleagues from Australia explored the epidemiology and disease burden of Hepatits B-related hepatocellular carcinoma.

The relative risks of hepatocellular carcinoma among people infected with hepatitis B virus ranges from 5 to 49 in case–control studies and from 7 to 98 in cohort studies.

More than 50% of hepatocellular carcinoma cases worldwide, and 70–80% of hepatocellular carcinoma cases in highly hepatitis B virus endemic regions are attributable to hepatitis B virus.

The team found that the incidence of hepatocellular carcinoma (per 100 000 person/year) among people with chronic hepatitis B virus infection ranges from 400 to 800 in male and from 120 to 180 in female.
Survival rates of hepatitis B virus-related hepatocellular carcinoma  ranged from 36% to 67% after 1 year.

Journal of Viral Hepatitis

Factors associated with increased risk of hepatocellular carcinoma  include demographic characteristics, and lifestyles.

In addition, viral factors (genotype C, D F, high level of hepatitis B virus  DNA, core/precore mutation), clinical factors (cirrhosis, elevated alpha-fetoprotein and alanine aminotransferase) increased the risk.

The researchers found that hepatitis B virus-related hepatocellular carcinoma has extremely poor prognosis with median survival less than 16 months.

Survival rates of hepatitis B virus-related hepatocellular carcinoma  ranged from 36% to 67% after 1 year, and from 15% to 26% after 5 year of diagnosis.

Older age, liver function impairment, vascular invasion, tumour aggressiveness and elevated AFP are associated with hepatocellular carcinoma  survival.

Global burden of hepatitis B virus -related liver disease is still a major challenge for public health in the 21st century.

The team found that while decreases in incidence of hepatitis B virus  infection have been observed in birth cohorts following the introduction of universal infant hepatitis B virus vaccination program.

Hepatitis B virus-related hepatocellular carcinoma incidence is projected to increase for at least 2 decades.

This projected increase is because of the high prevalence of chronic hepatitis B virus infection, and prolonged latency to hepatocellular carcinoma  development.

Dr Nguyen's team concluded, “To reduce hepatitis B virus-related hepatocellular carcinoma continued expansion of universal infant hepatitis B virus vaccination is required along with antiviral therapy targeted to those individuals at highest risk of hepatocellular carcinoma.”

“Broad public health strategies should include routine testing to identify chronic hepatitis B virus infection, improved health infrastructures including human resource to provide diagnosis and treatment assessment.”

J Vir Hep 2009: 16(7): 453-63
15 June 2009

Go to top of page Email this page Email this page to a colleague

 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis
 24 January 2018 
Ethnicity influences phenotype in IBD
 24 January 2018 
Bariatric surgery vs medical obesity treatment
 23 January 2018 
Atrophic gastritis after H. pylori eradication
 23 January 2018 
Ectopic pregnancy in women with IBD
 23 January 2018 
Celiac disease in IBS in the USA
 22 January 2018 
Costs of biologic therapies for IBD in the USA
 22 January 2018 
Western vs Asian guidelines for colon cancer management
 22 January 2018 
Improving symptoms in GERD
 19 January 2018 
Predicting the risk of early surgery in Crohn’s
 19 January 2018 
Ileoanal pouch microbiota
 19 January 2018 
Lifestyle intervention vs gastric bypass for obesity and diabetes
 18 January 2018 
Sleeve gastrectomy vs Roux-en-Y gastric bypass
 18 January 2018 
Healthcare costs of liver cancer in the USA
 18 January 2018 
High-risk adenomas at colonoscopy
 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Management of abnormal liver blood tests
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Early readmission in IBD patients

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us